Phase I/IIa
Promote Safe, Clinically Advanced Phase I/IIa Studies
You need to safely advance your drug candidate through phase I/IIa. The key to achieving this objective — on time — is to focus on maximizing critical data through strategic study design.
With five clinical phase I and phase IIa units in India, England, Sweden (2) and the United States, we offer:
- Study units across the globe — operating as one when sharing data and expertise
- Leading-edge, scientifically stringent analytical and technology solutions
- Proven study capabilities
- Complex
- Regulatory
- Vaccine
Detail-driven Phase I / Phase IIa Services, Processes and Staff
Together, we determine innovative and adaptive clinical study designs and Phase I/Phase IIa services required to reach your objectives. The result? Accurate, quality data to help you make faster, better informed decisions.
And throughout the study, our experts — leading authorities in early clinical trials phases research — consult and advise you. The impact? You receive the best actionable insight.